RGGC Physician Flowchart

FAQ

Do I need to pay for DHL shipping?
- No. The logistics expense is covered by RGCC.

How can I request glass vials for blood collection?
- Glass vials can be ordered through the RGCC portal. No charges apply.

How do I settle the test invoice?
- Payment can be made to RGCC SEA via bank transfer or through the online payment gateway.

What is the 'Incoming Sample Email'?
- This email confirms that the lab has received the sample and allows you to verify or amend the order details before processing begins.

How will I know when the test results are ready?
- You will receive an automated email from a "No Reply" address titled "You Have New Results in the Portal".

Can I request assistance in interpreting the test results?
- Yes. If clarification is needed, you may consult a RGCC Medical Advisor to arrange for a discussion.

What is the turnaround time for test results?
- Standard turnaround is 7 – 21 working days, depending on the test type.

+65 8084 6380
RGCCSEA
info@rgcc-seasia.com
rgccsea.com

Sample Report

Scan these **QR codes** to request sample report

RGCC

Shaping the cancer care paradigm

At RGCC, we strongly believe that personalized medicine is the future of cancer treatment. To improve the chances of successful treatment and survival, RGCC services help you to make informed decisions and formulate effective treatment plans.

Our team of scientists and medical experts conducts precise and reliable genetic tests to study cancer cells at all levels, as well as new therapeutic approaches.

RGCC REGIONAL OFFICE

RGCC Southeast Asia
2 Venture Drive #09-27 Vision Exchange
Singapore 608526
info@rgcc-seasia.com
+65 8084 6380

LABORATORY FACILITIES

RGCC International GmbH
Lindenstrasse 14
6340 Baar, Switzerland

Welmedis GmbH
Schönenbergstrasse 12
8820 Wädenswil, Switzerland

RGCC S.A.
Industrial Area of Florina
53100 Florina, Greece

RGCC Central Europe
Biozentrum, Weinbergweg 22
06120 Halle (Saale), Germany

RGCC India PVT LTD
Plot no 55, Road no 5
Aleap Industrial Area
Gajularamaram, Hyderabad, India

Member of RGCC GROUP

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

rgccsea.com

RGCC

Guided by science, driven by hope

Oncotrace

Monitoring and Therapeutics

rgccsea.com

Guiding Post-Diagnosis Decisions and Follow-Up Tool for Reactive Onco-D-clare Results

What

Oncotrace is a diagnostic test that detects, quantifies and analyses circulating tumour cells (CTCs) in the bloodstream. It provides insights into tumour presence, progression, and potential prognosis by analysing CTC count, immunophenotyping, and determining stemness markers.

Why

Oncotrace detects and analyses viable circulating tumour cells (CTCs) in blood. Unlike other tests that utilize ctDNA, CTCs offer real-time insights into tumour viability, metastasis, and treatment response. CTCs also capture tumour heterogeneity, including cancer stem cells subtype , often missed by ctDNA, providing a more functional, comprehensive view of cancer for personalized treatment planning.

Who

When to Order: Recommend for patients with diagnosed cancer or reactive Onco-D-clare results

Contraindications: Advise against use as a primary screening tool for asymptomatic individuals.
(*if you do not know the diagnosis -> Onco-D-clare)



HOW

- **Mechanism:** Targets viable CTC's which express specific markers
- **Process:** Isolation of malignant cells using flow cytometry with which the circulating tumor cells are enumerated and immunophenotyped

Test details

Sample type
Whole peripheral blood sample

Cancer type
Applicable for all cancer types

Final results
7-10 days after sample delivery



Sample size
25ml of whole peripheral blood

Analysis period
Approx. 7 days

Result:

Index of circulating cells number

If over limit: Advanced or progression of disease.
If less than limit: Early disease or disease is responding to a treatment plan

Breast Cancer	< 5 cells / 7.5 ml
Prostate Cancer	< 20 cells / ml
Sarcoma	< 15 cells / 6.5 ml
Colon Cancer	< 5 cells / ml
Lung Cancer	(Lc=0, r=0.99)< 10 cells / ml
All cancer types other than those listed above should be < 5 cells / ml	

Index of markers

CD44, CD133, Sox-2*, OKT-4*, Nanog*	Tumor stem cell marker
c-MET*	Membrane antigen that regulates the mesenchymal to epithelial transition
CD34*	Hematological stem cell and blast cell marker, epithelioid
CD45	Hematologic origin cell
BCR-ABL, CD30, CD15	Hematologic malignancy marker
CD19 (CD45 negative cells)	Lung neuroendocrine malignancy
CD19 (CD45 positive cells)	Hematological malignancy
CD31	Endothelial cell membrane antigen
CD63	Melanoma cell marker
CD99	Sarcoma marker
EpCam	Epithelial origin marker
MUC-1	Breast cancer antigen
PSMA	Prostate specific cancer stem cell membrane antigen
VHL mut	Renal carcinoma marker
panCK	Epithelial origin cell marker

Disclaimers

*This test will NOT DETECT cancers of the brain or other cancers that have been "encapsulated" by the body, not releasing circulating tumor or stem cells (CTC, CSC) into the blood stream or if any of these cells are dormant. We still recommend the use of biopsy, blood markers and/or various scans with this test when cancer is suspected or known to exist. No test is 100% accurate

*The methodology has a sensitivity of 86.2% and specificity of 83.9%. Sensitivity and specificity is calculated on actual clinical cases and clinical samples and not on spiked artificial samples

Oncotrace video

Oncotrace

Scan these **QR codes** know more about the Oncotrace

Note

- Oncotrace results can guide treatment decisions by providing information on tumor cell characteristics and activity.
- Regular monitoring with Oncotrace can help assess treatment efficacy and detect early signs of recurrence.